SC formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous (IV) formulation MISSISSAUGA, ON, Sept. 13, 2018 /CNW/ - Hoffmann-La Roche ...

Subcutaneous trastuzumab was considered non-inferior to intravenous trastuzumab. The incidence of Grade 3–5 adverse events was comparable between the groups, ...

Subcutaneous (SC) trastuzumab induced stromal tumor infiltrating lymphocyte (sTIL) enrichment and favorably varied immune parameters in patients with HER2-positive breast cancer with residual ...

Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery ...

Subcutaneous trastuzumab was observed to have a safety profile and efficacy similar to standard IV administration, offering a viable treatment alternative, according to study results published ...

"Our findings show that subcutaneous administration was significantly faster than intravenous administration across all measured outcomes, including patient time in the treatment chair (primary ...

Halozyme Therapeutics announced positive results from its Phase 3 HannaH study of subcutaneous (SC) Herceptin (trastuzumab) for the treatment of HER2-positive early breast cancer.

Subcutaneous delivery has been used for some time, including for well-known therapies such as trastuzumab (Herceptin), which is used in HER2-positive breast cancer, and bortezomib (Velcade), and ...

Embracing Subcutaneous Drugs in Lung Cancer and Beyond — Patients by far prefer subcutaneous to intravenous medication delivery, says Jorge Nieva, MD by Greg Laub , Director, Video, MedPage ...